Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in retinal amacrine cells | 0.75 |
| chemistry Open Targets | compounds already reach it: brivaracetam, seletracetam, levetiracetam +1 | 1.00 |
| trials ClinicalTrials.gov | 11 Parkinson's trials, 1 stopped | 0.93 |
| literature PubMed | 48 Parkinson's papers of 696 | 0.49 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2351
Sealed predictions
- SV2A in dopamine neurons, braak-0.45 (p 0.222) → +0.46 (p 0.215)receipt 2358
Swarm cases
receipt 2358: SV2A in dopamine neurons, braak
- power
- full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.867, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.585, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.24, sign flips 4; without severely affected donors +0.08 (p 0.754, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SV2A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts